Point72 Hong Kong LTD Mirati Therapeutics, Inc. Transaction History

Point72 Hong Kong LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $104,439 - $236,589	-2,667 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $202,211 - $402,636	2,667 New	2,667 $219,000
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $924,513 - $1.24 Million	-6,997 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $972,720 - $1.21 Million	6,755 Added 2791.32%	6,997 $1.13 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $10,647 - $14,847	-67 Reduced 21.68%	242 $41,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $50,073 - $74,243	309 New	309 $68,000
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $94,911 - $140,172	-838 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $60,344 - $100,886	838 New	838 $96,000
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $10,330 - $18,813	-146 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $11,374 - $16,001	146 New	146 $11,000
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $1,088 - $1,612	-34 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $1,601 - $2,131	34 New	34 $2,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.